|
NB: Concepts represent early planning stages for PAs, RFAs, or RFPs for Council 's input. Council approval does not guarantee that a concept will become an initiative.
If NIAID publishes an initiative from one of these concepts, we link to it below. For a full list of initiatives, go to NIH Funding Opportunities Relevant to NIAID.
Table of Contents
Microbiology and Infectious Diseases Biological Resource Repository
Request for Proposals
Contact: Nicole Gordon
Phone: 301-402-4925
Internet: gordonn@niaid.nih.gov
Objective: To acquire, authenticate, produce, store, and distribute research and reference organisms and reagents to support microbiological and infectious diseases research.
Description: The Microbiology and Infectious Diseases Biological Resource Repository (MID-BRR) will serve as a central repository that will provide acquisition, authentication, production, storage, and distribution of organisms through a central ordering system to the broad community of microbiology and infectious diseases researchers. While the MID-BRR will meet most needs, the acquisition, production, and authentication of some microbes can be provided only by individuals with highly specialized expertise, facilities, and/or resources. Such specialized expertise and resources will be provided through the Microbiology and Infectious Diseases Specialized Biological Resources (MID-SBR) program, as well as the Animal Models of Infectious Diseases program. Numerous, pathogen-specific DMID repositories will be brought into this unified program in order to achieve efficient use of resources through economy of scale and avoidance of duplication, and provide flexibility to respond to changing priorities while maintaining critical reagents and collections.
Microbiology and Infectious Diseases Specialized Biological Resources
Request
for Proposals
Contact: Bijan Mansoury
Phone: 301-594-4573
Internet: mansouryb@niaid.nih.gov
Objective: To provide specialized expertise and resources essential for acquisition, production, authentication, and distribution of Mycobacteria, emerging viruses, and arboviruses, including organisms requiring BSL-4 containment, and reagents integral to research on these organisms.
Description: The Microbiology and Infectious Diseases Specialized Biological Resources (MID-SBR) will produce, authenticate, and distribute organisms such as Mycobacteria, emerging viruses, and arboviruses, as well as organisms requiring BSL-4 containment, and reagents integral to research on these organisms. Where appropriate, organisms and reagents will be shipped to the Microbiology and Infectious Diseases Biological Resource Repository (MID-BRR), which will serve as a central repository and maintain a central ordering system. While the MID-BRR can meet most needs, the acquisition, production, and authentication of Mycobacteria and the extensive collection of emerging viruses and arboviruses can be provided only by individuals with highly specialized expertise and resources, including those for BSL-4 containment. Therefore, this separate initiative will establish the MID-SBR program as a complement to the MID-BRR.
In Vitro Assessments for Antimicrobial Activity
Request for Proposals
Contact: Harry Brubaker
Phone: 301-402-6289
Internet: brubakerh@niaid.nih.gov
Objective: To provide a variety of in vitro screening services, primarily to assess the antimicrobial activity (antiviral, antibacterial, antifungal, anti-mycobacterial, and/or antiparasitic) of compounds supplied by grantees, contractors, industry, etc.
Description: These contracts will provide in vitro screening for antimicrobial activity against a wide variety of pathogens, including newly emerged, highly pathogenic, and/or drug-resistant strains, and aid in the development of broad spectrum drugs. A task-driven approach will allow DMID to respond to emerging pathogens by developing screening assays upon identification of new infectious agents. Bringing all in vitro screening within DMID into one unified program should provide flexibility to respond to changing priorities while maintaining critical capabilities.
Animal Models of Infectious Diseases
For the published initiative, see the October 15, 2008, solicitation.
Request for Proposals
Contact: Brian Jamieson
Phone: 301-451-3678
Internet: bjamieson@niaid.nih.gov
Objective: To develop new animal models of infectious diseases and provide infectious disease animal model resources to advance promising products and share research resources with the scientific community through programmatic meetings, technology transfer, and deposits into the Microbiology and Infectious Diseases Biological Resource Repository.
Description: The contracts will provide for the development of new animal models, use of existing animal models to screen new vaccines and therapeutics for efficacy, and testing and evaluation of priority therapeutics and vaccines, including GLP models, for pivotal animal efficacy testing. The contracts will also produce biological research resources for microbes, such as leprosy and parasites, that can be provided only by individuals with specialized expertise and resources for distribution through the Microbiology and Infectious Diseases Biological Resource Repository. Numerous animal model contracts will be brought into one unified program in order to achieve efficient use of resources through economy of scale, avoidance of duplication, and a task-driven approach to provide flexibility to respond to changing priorities while maintaining critical capabilities and providing consistency.
DMID Clinical Research Operations and Support
Request for Proposals
Contact: Debby Baca
Phone: 301-443-4490
Internet: dbaca@niaid.nih.gov
Objective: To provide clinical research support, including clinical site monitoring, safety data monitoring, site quality management, protocol development, and research information tracking databases and other operational, administrative, and logistical support.
Description: This initiative will provide safety tracking, site assessment, clinical site monitoring, and oversight for over 200 DMID clinical research studies at more than 100 domestic and foreign clinical sites. It will provide tools and templates for protocol and document development, GCP training, management and support of DMID safety monitoring committees, and training and oversight of site quality management.
Innovative Approaches to Target Identification and Assay Development for Fungal Diagnosis
For the published initiative, see the September 23, 2008, Guide announcement.
Request for Applications
Contact: Rory Duncan
Phone: 301-402-8613
Internet: rduncan@niaid.nih.gov
Objective: To foster a collaborative effort between the mycology research community and technology-based entities to explore emerging and innovative technologies for diagnostic target identification with samples generated through the central animal model resource.
Description: This initiative will focus on emerging technologies in an effort to identify microbial and host components as potential diagnostic targets for invasive aspergillosis. The initiative will also foster innovative collaborations between the mycology research community and technology-based entities to explore proteomics, metabolomics, and glycoproteomics, which may lead to the identification of novel diagnostic targets for fungal infections. Species-specific target identification with animal model samples of Aspergillus fumigatus will be supported. The target identification can be followed by assay development and validation.
This initiative is designed to foster investigator-initiated research at the earliest stages of concept genesis and evaluation. It is the intent of the combined R21/R33 approach to effectively ensure timely translational funding of the most promising preclinical approaches in an effort to significantly expedite transition of meritorious, milestone-driven projects from the R21 feasibility phase to the R33 development phase. Investigators are required to submit the R21 and R33 phases as one application. Following review, those applicants determined to be highly meritorious will be required to pre-negotiate with program the specific milestones to be completed during the R21 phase, and the milestones will be incorporated into the terms of award. R33 funding will depend upon program priorities, availability of funds, and successful completion of negotiated, quantitative milestones, as determined by NIH staff in the context of the initial peer review. The negotiated R21 phase milestones must be completed before funds are released for the R33 phase. Program determines whether negotiated milestones were successfully met, and in successful cases, then expedites the transition to the R33 phase. The expectation is that the expansion and modification elements of this phased innovation award program will spark interest among active researchers, and possibly attract top new PIs into the field.
Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance
Broad Agency Announcement
Contact: Frank Vidergar
Phone: 301-402-1490
Internet: vidergarf@niaid.nih.gov
Objective: To conduct targeted clinical trials to address the growing public health problem of antimicrobial resistance.
Description: This initiative will support the conduct of clinical trials targeting areas of greatest antimicrobial drug exposure in order to make the biggest impact on reducing selective antimicrobial drug pressure. Eligible research areas include pneumonia, otitis media, urinary tract infection, and bacteremia. Both community and hospital settings will be sought. Eligible strategies include, but are not limited to: shorter courses of antimicrobial treatment in various diseases; withholding antimicrobials where not indicated; different dosages/frequencies to achieve desirable in vivo efficacy; prudent antimicrobial use; optimal use of off-patent antimicrobials for newly emerging resistance; and new indications for licensed products.
|
